May 18, 2020 -- “We believe the randomized head-to-head comparison of leronlimab to remdesivir and in combination will provide answers to the lingering question regarding effective treatment options for patients suffering from COVID-19. We look forward to working both in the United States and with potential international sites to help provide effective treatment options for COVID-19,” said Jacob Lalezari, M.D., Chief Science Officer of CytoDyn.

& what was the date of Murray's "NEVER" e-mail comment again ??

You're dam right, lots of smoke....